TrialBMC infectious diseases2025

Daily single-strength vs. thrice-weekly double-strength trimethoprim/sulfamethoxazole for Pneumocystis jirovecii prophylaxis in kidney transplant recipients: a non-inferiority randomized control trial.

Wittawin Chantapoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.